ArticleCancer immunology, immunotherapy : CII2025
Real-world treatment practices and survival outcomes of patients with de novo metastatic nasopharyngeal carcinoma after chemoimmunotherapy.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The current role of immunotherapy in treating nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2026Review
- Survival and patterns of recurrence in patients with nasopharyngeal carcinoma from a non-endemic region-A German multicenter analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo evaluate the real-world treatment practices and survival outcomes of patients with de novo metastatic nasopharyngeal carcinoma (dnMNPC) after the combination of programmed death-1(PD-1) inhibitors with chemotherapy.
methodsWe retrospectively gathered data from patients with dnMNPC who were treated with a combination of chemotherapy and PD-1 inhibitors between August 2019 and August 2023. Kaplan-Meier analysis and Cox proportional hazards regression model were used for statistical analyses.
resultsA total of 42 patients with dnMNPC were included. There were 22 and 20 patients who had oligometastasis (OM) (52.3%) and polymetastasis (PM) (47.6%), respectively. After systemic chemotherapy and PD-1 inhibitor treatment, 20 patients (47.6%) received locoregional radiotherapy. Over the entire course of chemotherapy and PD-1 inhibitor treatment, the patient cohort comprised 10 cases of complete response (23.8%), 27 cases of partial response (64.3%), 3 cases of stable disease (7.1%), and 2 cases of progressive disease (4.8%). The observed response rate was 88.1%. With a median follow-up duration of 19.4 months, the 2-year progression-free survival (PFS) and overall survival (OS) were 32.0% and 70.7%, respectively. Patients with PM (PFS, P = 0.021; OS, P = 0.009) and had detectable EBV-DNA (PFS, P = 0.051; OS, P = 0.005) post-treatment had inferior PFS and OS.
conclusionsThe addition of PD-1 inhibitors to chemotherapy offers better clinical efficacy for patients with dnMNPC. Patients with OM and undetectable EBV-DNA after chemoimmunotherapy exhibit improved survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.